Anika Therapeutics (NASDAQ: ANIK) and 3SBio (NASDAQ:SSRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Insider & Institutional Ownership

84.9% of Anika Therapeutics shares are owned by institutional investors. 6.6% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Anika Therapeutics and 3SBio’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $103.38 million 7.95 $32.54 million $2.13 26.31
3SBio N/A N/A N/A $0.73 22.73

Anika Therapeutics has higher revenue and earnings than 3SBio. 3SBio is trading at a lower price-to-earnings ratio than Anika Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and price targets for Anika Therapeutics and 3SBio, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 0 1 0 3.00
3SBio 0 0 1 0 3.00

Anika Therapeutics currently has a consensus target price of $57.00, indicating a potential upside of 1.73%. Given Anika Therapeutics’ higher possible upside, research analysts plainly believe Anika Therapeutics is more favorable than 3SBio.

Volatility and Risk

Anika Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, 3SBio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500.

Profitability

This table compares Anika Therapeutics and 3SBio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 28.23% 13.40% 12.41%
3SBio N/A N/A N/A

Summary

Anika Therapeutics beats 3SBio on 9 of the 10 factors compared between the two stocks.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc. is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. The Company’s therapeutic offerings consist of products in the areas, including Orthobiologics, which includes viscosupplementation and regenerative orthopedic products; Dermal, which includes wound care products; Surgical, which includes products used to prevent post-surgical adhesions, and Other, which includes the Company’s ophthalmic and veterinary products. The Company also offers products made from HA based on two other technologies: HYAFF, which is a solid form of HA, and ACP gel, an autocross-linked polymer of HA.

3SBio Company Profile

3SBio Inc. is a biotechnology company in the People’s Republic of China with research and development, manufacturing, and marketing capabilities focusing on bio-pharmaceutical products. The Company recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO. In addition, it has two legacy products, Intefen and Inleusin; and an in-licensed product, Iron Sucrose Supplement. The Company focuses on its research and development efforts on both novel and validated protein-based therapeutics for the treatment of diseases in the areas of nephrology, oncology, supportive cancer care, inflammation and infectious diseases, and other selected areas. In May 2013, the Company merged with Decade Sunshine Limited and Decade Sunshine Merger Sub.

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.